FDA Cybersecurity Guidance
How Scrutex Supports FDA Cybersecurity Requirements for Medical Devices
Executive Summary
The FDA's 2023 cybersecurity guidance, backed by the PATCH Act's statutory authority, makes cybersecurity a regulatory requirement for medical device premarket submissions. The emphasis on total product lifecycle security, SBOM transparency, and post-market monitoring demands capabilities beyond traditional product testing. Scrutex supports device manufacturers and healthcare organisations with continuous monitoring of the device ecosystem's external exposure, supply chain oversight, vulnerability tracking, and threat intelligence relevant to medical device security.
About FDA Cybersecurity Guidance
The FDA guidance requires manufacturers to consider cybersecurity from initial design through deployment and ongoing maintenance. Key requirements include a Software Bill of Materials (SBOM), a post-market vulnerability management plan, and demonstrated security testing. A core theme is transparency: manufacturers must show regulators and healthcare organisations that devices are designed with security from the outset and that vulnerabilities will be managed throughout the product lifecycle.
Geographic and Sector Applicability
The guidance applies to manufacturers of 'cyber devices' including any device with software, internet connectivity, or cybersecurity vulnerabilities. International manufacturers seeking FDA clearance must comply. Healthcare delivery organisations are indirectly affected, as they must manage deployed device security and may look to manufacturers for assurance.
Who Should Care
Product Security / CISO
Owns cybersecurity design, testing, and post-market monitoring for the device portfolio.
Regulatory Affairs
Must include comprehensive cybersecurity documentation in premarket submissions.
Software Engineering
Responsible for SBOM management and secure development practices.
Supply Chain / Procurement
Must manage software component vendors and track third-party vulnerabilities.
Key Risks of Non-Compliance
FDA has statutory authority to refuse premarket submissions lacking cybersecurity information.
Refusal to accept premarket submissions (510(k), De Novo, PMA) that lack required cybersecurity documentation.
Post-market enforcement actions for failure to maintain adequate vulnerability management.
Loss of US market access, one of the largest medical device markets globally.
Healthcare organisation procurement decisions increasingly favour manufacturers with demonstrated cybersecurity commitment.
Common Compliance Gaps
Incomplete SBOM and Supply Chain Visibility
Many manufacturers lack comprehensive visibility into the third-party software components in their devices and the security posture of their component suppliers.
Limited Post-Market Monitoring
Premarket security testing is necessary but insufficient. Post-market vulnerability monitoring across the device ecosystem is often underdeveloped.
No Threat Intelligence for Medical Devices
Medical device threat intelligence is specialised. Generic IT security intelligence often misses threats specific to device platforms and healthcare infrastructure.
How Scrutex Supports FDA Cybersecurity Guidance Compliance
Scrutex capabilities mapped to FDA Cybersecurity Guidance requirements.
The FDA requires manufacturers to understand their device's attack surface and monitor for post-market vulnerabilities. Scrutex identifies and monitors external-facing device ecosystem components including cloud APIs, firmware update servers, device management platforms, and backend infrastructure.
Scrutex Capabilities
- ✓Device ecosystem attack surface monitoring
- ✓Cloud backend vulnerability assessment
- ✓API exposure detection
- ✓Certificate monitoring
Requirements Addressed
- Threat modelling and attack surface analysis
- Post-market cybersecurity management
Scrutex monitors for exposure of device-related information including source code, firmware, API keys, and configuration data. Source code leakage for medical device firmware could reveal exploitable vulnerabilities, making this a critical monitoring capability.
Scrutex Capabilities
- ✓Source code leakage detection
- ✓API key exposure monitoring
- ✓Dark web surveillance for device-related intelligence
- ✓Paste site monitoring
Requirements Addressed
- Post-market cybersecurity surveillance
- Vulnerability disclosure readiness
The SBOM requirement reflects supply chain security concerns. Scrutex enables manufacturers to continuously monitor the security posture of software component providers, cloud service providers, and contract manufacturers.
Scrutex Capabilities
- ✓Software supplier security monitoring
- ✓Cloud provider assessment
- ✓Supply chain risk scoring
Requirements Addressed
- SBOM management
- Supply chain risk assessment
Scrutex provides threat intelligence relevant to medical device platforms, including CVE tracking for device components, threat actor monitoring for groups targeting healthcare, and ransomware intelligence for the healthcare sector.
Scrutex Capabilities
- ✓CVE repository with medical device relevance
- ✓Healthcare threat actor tracking
- ✓Ransomware intelligence
- ✓IOC collection
Requirements Addressed
- Threat intelligence for device security
- Post-market threat monitoring
Compliance Reporting
Scrutex's reporting supports premarket submission documentation and post-market management plan evidence with structured reports covering external security posture, vulnerability status, and supply chain oversight.
Scrutex Capabilities
- ✓Premarket submission evidence
- ✓Post-market management documentation
- ✓Supply chain oversight reports
Requirements Addressed
- Premarket submission documentation
- Post-market management plan evidence
Quick-Start Compliance Checklist
Map your device ecosystem's external footprint using Vulnerability Insights.
Onboard key software and cloud suppliers into Vendor Insights.
Activate Data Exposure Insights for source code and firmware leakage monitoring.
Enable Threat Insights for medical device and healthcare threat intelligence.
Generate documentation supporting your premarket submission or post-market management plan.
Summary
The FDA's 2023 cybersecurity guidance makes security a regulatory requirement for market access. The total product lifecycle approach demands capabilities that extend beyond traditional premarket testing to encompass continuous monitoring, supply chain oversight, and proactive threat intelligence. Scrutex supports manufacturers in meeting these requirements with continuous visibility into the device ecosystem, supply chain monitoring, data exposure detection, medical device threat intelligence, and compliance documentation.
Related Regulations and Standards
HIPAA / HITECH: Healthcare organisations deploying devices must comply with both FDA guidance and HIPAA.
IMDRF Cybersecurity: IMDRF guidance provides the international harmonised framework that FDA guidance aligns with.
IEC 62443: IEC 62443 is referenced for industrial control system aspects of medical devices.
EU MDR / Cyber Resilience Act: Manufacturers seeking EU market access face similar cybersecurity requirements.
Ready to Strengthen Your Compliance Posture?
Book a personalised demonstration and receive a complimentary external exposure assessment.